[Myocardial regeneration with cell transplantation therapy].

Jun Fujita, Keiichi Fukuda

Research output: Contribution to journalArticle

Abstract

Morbidity and mortality in heart failure (HF) remain high in developed countries. Cardiac regenerative therapy with stem cells has the potential to improve the treatment of HF. Several cell sources have been investigated for cardiac cell transplantation therapy. The most representative cell sources are bone marrow stem cells, skeletal myoblasts, and cardiac progenitor cells. Skeletal myoblasts raise the issue of arrhythmo-genicity. Regenerative cardiomyocytes derived from human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) are the most promising, because ESCs and iPSCs can potentially generate both contraction recovery and electromechanical coupling with host cardiomyocytes. The functional mechanism of myocardial cell transplantation therapy may be cardiac differentiation, cytokine effects, neovascularization, and intrinsic cardiac progenitor differentiation. It is critical to establish the differentiation protocol from hESCs and hiPSCs to cardiomyocytes. The survival of transplanted cells is also very important. The clinical application of myocardial cell therapy is anxiously awaited for the treatment of HF.

Original languageEnglish
Pages (from-to)441-445
Number of pages5
JournalNihon Geka Gakkai zasshi
Volume113
Issue number5
Publication statusPublished - 2012 Sep
Externally publishedYes

Fingerprint

Cell Transplantation
Cell- and Tissue-Based Therapy
Cardiac Myocytes
Skeletal Myoblasts
Regeneration
Induced Pluripotent Stem Cells
Stem Cells
Heart Failure
Treatment Failure
Heart Transplantation
Developed Countries
Bone Marrow Cells
Cell Survival
Cytokines
Morbidity
Mortality
Human Embryonic Stem Cells
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Myocardial regeneration with cell transplantation therapy]. / Fujita, Jun; Fukuda, Keiichi.

In: Nihon Geka Gakkai zasshi, Vol. 113, No. 5, 09.2012, p. 441-445.

Research output: Contribution to journalArticle

@article{2c7d24a305b144d9b5615d67e2ed5a73,
title = "[Myocardial regeneration with cell transplantation therapy].",
abstract = "Morbidity and mortality in heart failure (HF) remain high in developed countries. Cardiac regenerative therapy with stem cells has the potential to improve the treatment of HF. Several cell sources have been investigated for cardiac cell transplantation therapy. The most representative cell sources are bone marrow stem cells, skeletal myoblasts, and cardiac progenitor cells. Skeletal myoblasts raise the issue of arrhythmo-genicity. Regenerative cardiomyocytes derived from human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) are the most promising, because ESCs and iPSCs can potentially generate both contraction recovery and electromechanical coupling with host cardiomyocytes. The functional mechanism of myocardial cell transplantation therapy may be cardiac differentiation, cytokine effects, neovascularization, and intrinsic cardiac progenitor differentiation. It is critical to establish the differentiation protocol from hESCs and hiPSCs to cardiomyocytes. The survival of transplanted cells is also very important. The clinical application of myocardial cell therapy is anxiously awaited for the treatment of HF.",
author = "Jun Fujita and Keiichi Fukuda",
year = "2012",
month = "9",
language = "English",
volume = "113",
pages = "441--445",
journal = "Nihon Geka Gakkai zasshi",
issn = "0301-4894",
publisher = "Nihon Geka Gakkai",
number = "5",

}

TY - JOUR

T1 - [Myocardial regeneration with cell transplantation therapy].

AU - Fujita, Jun

AU - Fukuda, Keiichi

PY - 2012/9

Y1 - 2012/9

N2 - Morbidity and mortality in heart failure (HF) remain high in developed countries. Cardiac regenerative therapy with stem cells has the potential to improve the treatment of HF. Several cell sources have been investigated for cardiac cell transplantation therapy. The most representative cell sources are bone marrow stem cells, skeletal myoblasts, and cardiac progenitor cells. Skeletal myoblasts raise the issue of arrhythmo-genicity. Regenerative cardiomyocytes derived from human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) are the most promising, because ESCs and iPSCs can potentially generate both contraction recovery and electromechanical coupling with host cardiomyocytes. The functional mechanism of myocardial cell transplantation therapy may be cardiac differentiation, cytokine effects, neovascularization, and intrinsic cardiac progenitor differentiation. It is critical to establish the differentiation protocol from hESCs and hiPSCs to cardiomyocytes. The survival of transplanted cells is also very important. The clinical application of myocardial cell therapy is anxiously awaited for the treatment of HF.

AB - Morbidity and mortality in heart failure (HF) remain high in developed countries. Cardiac regenerative therapy with stem cells has the potential to improve the treatment of HF. Several cell sources have been investigated for cardiac cell transplantation therapy. The most representative cell sources are bone marrow stem cells, skeletal myoblasts, and cardiac progenitor cells. Skeletal myoblasts raise the issue of arrhythmo-genicity. Regenerative cardiomyocytes derived from human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) are the most promising, because ESCs and iPSCs can potentially generate both contraction recovery and electromechanical coupling with host cardiomyocytes. The functional mechanism of myocardial cell transplantation therapy may be cardiac differentiation, cytokine effects, neovascularization, and intrinsic cardiac progenitor differentiation. It is critical to establish the differentiation protocol from hESCs and hiPSCs to cardiomyocytes. The survival of transplanted cells is also very important. The clinical application of myocardial cell therapy is anxiously awaited for the treatment of HF.

UR - http://www.scopus.com/inward/record.url?scp=84872007668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872007668&partnerID=8YFLogxK

M3 - Article

C2 - 23061366

AN - SCOPUS:84872007668

VL - 113

SP - 441

EP - 445

JO - Nihon Geka Gakkai zasshi

JF - Nihon Geka Gakkai zasshi

SN - 0301-4894

IS - 5

ER -